Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT05032183 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped The study was terminated early due to slow enrollment.

Conditions

Recurrent Adult Lymphoblastic Lymphoma
Recurrent B Acute Lymphoblastic Leukemia
Recurrent T Acute Lymphoblastic Leukemia
Refractory B Acute Lymphoblastic Leukemia
Refractory Lymphoblastic Lymphoma
Refractory T Acute Lymphoblastic Leukemia

Interventions

DRUG: Cyclophosphamide
DRUG: Cytarabine
DRUG: Dexamethasone
BIOLOGICAL: Filgrastim-sndz
DRUG: Leucovorin
DRUG: Mercaptopurine
DRUG: Mesna
DRUG: Methotrexate
BIOLOGICAL: Pegfilgrastim
DRUG: Prednisone
BIOLOGICAL: Rituximab
BIOLOGICAL: Tagraxofusp-erzs
DRUG: Vincristine

Sponsor

M.D. Anderson Cancer Center